TimesSquare Capital Management LLC Acquires 640,329 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

TimesSquare Capital Management LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 250.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 895,574 shares of the company's stock after buying an additional 640,329 shares during the quarter. TimesSquare Capital Management LLC owned about 0.97% of NewAmsterdam Pharma worth $23,016,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. Quarry LP grew its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after acquiring an additional 6,247 shares in the last quarter. Barclays PLC grew its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new position in shares of NewAmsterdam Pharma in the third quarter valued at approximately $128,000. Finally, HB Wealth Management LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $224,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the transaction, the insider now directly owns 10,908,502 shares of the company's stock, valued at approximately $284,711,902.20. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 404,927 shares of company stock valued at $10,390,787 over the last 90 days. 19.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

NAMS has been the topic of several research analyst reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC restated a "buy" rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. HC Wainwright restated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Scotiabank increased their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of "Buy" and an average price target of $41.60.

NewAmsterdam Pharma Stock Down 2.3 %

NAMS traded down $0.43 during trading on Friday, reaching $18.57. The stock had a trading volume of 565,249 shares, compared to its average volume of 618,215. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The business has a 50-day moving average of $23.17 and a 200-day moving average of $20.18.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.